

Embolotherapy Market by Product (Embolic Agents (Microspheres, Liquid Embolic Agents, Coil), Microcatheters), Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology), Procedure (TACE, TARE), Enduser (Hospital, Clinics, ASC) - Global Forecast to 2026

<https://marketpublishers.com/r/E3794B95A04EN.html>

Date: May 2021

Pages: 222

Price: US\$ 4,950.00 (Single User License)

ID: E3794B95A04EN

Abstracts

The global embolotherapy market is valued at USD 3.4 billion in 2021 and is expected to reach USD 5.0 billion by 2026, at a CAGR of 8.0% during the forecast period. The growth of this market is primarily driven by the rising burden of target diseases and increasing investments, funds, and grants for the development of novel products. Moreover, increasing demand for minimally invasive procedures, favorable reimbursement scenario, and new product launches in the market are further supporting the growth of the market over the forecast period. However, stringent regulatory frameworks for product commercialization and the strong market positioning of alternative treatments are expected to limit the optimal adoption of embolotherapy devices during the forecast period.

“The cancer segment, by application, accounted for the largest share of the embolotherapy market in 2020”

In terms of application, embolotherapy market is classified into cancer, peripheral vascular diseases, neurological diseases, urological & nephrological disorders, and gastrointestinal disorders. The high success rate and less post-operative complication rate associated with embolotherapy procedures coupled with the rising incidences of liver cancer and hepatocellular cancer are the key factors fueling the demand for embolotherapy devices for cancer disease indication. For instance, liver cancer is the

fifth most common cancer in men and the ninth most common in women.

“The embolic agents segment, by product, is to register a significant growth rate owing to new product approvals”

Based on product, the embolotherapy market is broadly segmented into embolization coils (detachable coils and pushable coils), embolic agents (liquid embolic agents and microspheres), detachable balloons, embolic plug systems, and support devices (microcatheters and guidewires). The embolic agents segment is anticipated to register the highest growth over the forecast period owing to new product approvals and launches in the segment. For instance, in 2019, Terumo received the FDA Premarket Approval (PMA) for the ‘WEB Aneurysm Embolization System.’ Moreover, in 2018, Medtronic launched OptiSphere embolization spheres in the US as well as the Concerto 3D detachable coil system in Ireland.

“Increasing availability of reimbursements in most of developed countries to drive the segment growth of ambulatory surgical centers end user segment”

Based on end users, the embolotherapy market is segmented into hospitals and clinics, ambulatory surgery centers (ASCs), and other end users. The ambulatory surgery centers segment is projected to register the highest CAGR during the forecast period. The significant growth of this segment can be attributed to the growing adoption of minimally invasive surgical procedures, the increasing number of procedures in ambulatory surgery centers, and the greater availability of reimbursements for target procedures in the US and major European countries.

“The US market, by region, commanded the largest market share in 2020”

On the basis of region, the embolotherapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The US held the major share of the global embolotherapy market in 2018. Factors such as the favorable reimbursement scenario in the US, growing target patient population (CVDs, neurovascular diseases, cancer, and uterine fibroids), increasing preference for minimally invasive procedures, new product launches and technological advancements in embolotherapy devices, and the presence of key players in the region are driving the growth of the embolotherapy market in the US.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–45%, Tier 2–34%, and Tier 3– 21%

By Designation: C-level–47%, Director-level–33%, and Others–20%

By Region: North America–35%, Europe–32%, Asia Pacific–25%, Latin America–6%, and the Middle East & Africa–2%

Some of the prominent players in the embolotherapy market Boston Medical Corporation (US), Terumo Medical Systems (Japan), Medtronic (US), Johnson & Johnson (US), and Stryker Corporation (US). Other key players in the embolization therapy market include Sirtex Medical Limited (US), Abbott Laboratories (US), Acandis GmbH (Germany), Balt (France), Cook Medical (US), Kaneka Corporation (Japan), Penumbra, Inc. (US), Merit Medical Systems (US), Meril Life Sciences Pvt. Ltd. (India), Cardiva (US), Shape Memory Medical Inc. (US), Artio Medical Inc. (US), Rapid Medical (US), Emboline, Inc. (US), and IMbiotechnologies Ltd. (Canada), among others.

Research Coverage

This report studies the embolotherapy market based on product, procedure, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios offered by the top players in the embolotherapy market

Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the embolotherapy market

Market Development: Comprehensive information on lucrative emerging regions

Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the embolotherapy market

Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

Contents

1 INTRODUCTION

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
 - 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
- 1.3 MARKET SCOPE
 - 1.3.1 MARKETS COVERED
 - 1.3.2 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY USED FOR THE STUDY
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - FIGURE 1 RESEARCH DESIGN
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 An indicative list of secondary sources
 - 2.1.2 PRIMARY DATA
 - FIGURE 2 BREAKDOWN OF PRIMARIES: EMBOLOThERAPY MARKET
- 2.2 MARKET ESTIMATION METHODOLOGY
 - FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
 - 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
 - 2.2.2 PRODUCT-BASED MARKET ESTIMATION
 - FIGURE 4 MARKET SIZE ESTIMATION: EMBOLOThERAPY MARKET
 - 2.2.3 PRIMARY RESEARCH VALIDATION
- 2.3 DATA TRIANGULATION
 - FIGURE 5 DATA TRIANGULATION METHODOLOGY
- 2.4 RESEARCH ASSUMPTIONS
- 2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

FIGURE 6 EMBOLOThERAPY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)

FIGURE 7 EMBOLOThERAPY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)

FIGURE 8 EMBOLOThERAPY MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION)

FIGURE 9 EMBOLOThERAPY MARKET SHARE, BY END USER, 2021 VS. 2026

FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE EMBOLOThERAPY MARKET

4 PREMIUM INSIGHTS

4.1 EMBOLOThERAPY: MARKET OVERVIEW

FIGURE 11 THE RISING INCIDENCE OF CHRONIC DISEASES IS A KEY FACTOR DRIVING MARKET GROWTH

4.2 GEOGRAPHIC ANALYSIS: NORTH AMERICA EMBOLOThERAPY MARKET, BY PRODUCT, 2021 VS 2026, (USD MILLION)

FIGURE 12 THE EMBOLIC AGENTS SEGMENT WILL WITNESS HIGH GROWTH IN THE NORTH AMERICA MARKET IN 2026

4.3 EMBOLOThERAPY MARKET, BY APPLICATION, 2021 VS 2026, (USD MILLION)

FIGURE 13 THE LIVER CANCER SUBSEGMENT OF THE ONCOLOGY APPLICATION IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD

4.4 EMBOLOThERAPY MARKET, BY REGION AND PROCEDURE

FIGURE 14 TRANSARTERIAL EMBOLIZATION (TAE) PROCEDURE SEGMENT TO HOLD A MAJOR SHARE OF THE ASIA PACIFIC MARKET

4.5 GEOGRAPHIC ANALYSIS: EMBOLOThERAPY MARKET, BY END USER AND REGION, 2021 VS. 2026 (USD MILLION)

FIGURE 15 AMBULATORY SURGICAL CENTERS SEGMENT TO WITNESS HIGH GROWTH IN EUROPE DURING THE FORECAST PERIOD

4.6 GEOGRAPHIC SNAPSHOT OF THE EMBOLOThERAPY MARKET

FIGURE 16 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 17 EMBOLOThERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Growing target patient population

TABLE 1 PRIMARY INCIDENCE OF LIVER CANCER AMONG MEN AND WOMEN (2005 VS. 2030)

TABLE 2 GERIATRIC POPULATION, BY REGION (2015 VS. 2030)

- 5.2.1.2 Rising patient preference for minimally invasive procedures
- 5.2.1.3 Funding & investments by government and private organizations
- 5.2.1.4 Technological advancements in embolotherapy devices
- 5.2.1.5 Favorable reimbursement scenario for minimally invasive surgeries

TABLE 3 MEDICAL REIMBURSEMENT CPT CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2021)**TABLE 4 MEDICAL REIMBURSEMENT MS-DRG CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2019)****5.2.2 RESTRAINTS**

- 5.2.2.1 Lack of sufficient evidence & unfavorable regulatory scenario
- 5.2.2.2 Strong market positioning of alternative therapies

5.2.3 OPPORTUNITIES

- 5.2.3.1 Growth opportunities offered by emerging markets
- 5.2.3.2 Expanding applications of embolization devices

5.2.4 CHALLENGES

- 5.2.4.1 A dearth of skilled surgeons
- 5.2.4.2 High cost of embolization devices

5.3 VALUE CHAIN ANALYSIS**FIGURE 18 VALUE CHAIN ANALYSIS****5.4 ECOSYSTEM: EMBOLOTHERAPY MARKET****5.5 REGULATORY ANALYSIS****5.5.1 NORTH AMERICA****5.5.1.1 US****TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION****TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS****5.5.1.2 Canada****TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS****FIGURE 19 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES****5.5.2 EUROPE****FIGURE 20 EUROPE: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES (MDR)****5.5.3 ASIA PACIFIC****5.5.3.1 Japan****TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)****5.5.3.2 China****TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES**

5.5.3.3 India

5.6 IMPACT OF COVID-19 ON EMBOLOThERAPY MARKET

TABLE 10 COVID-19 GUIDELINES FOR TRIAGE OF VASCULAR SURGERY PATIENTS

6 EMBOLOThERAPY MARKET, BY PRODUCT

6.1 INTRODUCTION

TABLE 11 EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

6.2 EMBOLIC AGENTS

TABLE 12 EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 13 EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY REGION, 2019–2026 (USD MILLION)

TABLE 14 EMBOLIC AGENTS, BY TYPE

6.2.1 LIQUID EMBOLIC AGENTS

6.2.1.1 Significant adoption of embolic coils due to their procedural benefits over liquid embolic agents is expected to restrict the market growth

TABLE 15 EMBOLOThERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2019–2026 (USD MILLION)

6.2.1.2 Embolotherapy market for liquid embolic agents, by application

TABLE 16 EMBOLOThERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY APPLICATION, 2019–2026 (USD MILLION)

6.2.1.3 Embolotherapy market for liquid embolic agents, by Procedure

TABLE 17 EMBOLOThERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY PROCEDURE, 2019–2026 (USD MILLION)

6.2.1.4 Embolotherapy market for liquid embolic agents, by end user

TABLE 18 EMBOLOThERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY END USER, 2019–2026 (USD MILLION)

6.2.2 MICROSPHERES

6.2.2.1 Preference for alternative procedures limits the growth of this market segment

TABLE 19 EMBOLOThERAPY MARKET FOR MICROSPHERES, BY REGION, 2019–2026 (USD MILLION)

6.2.2.2 Embolotherapy market for microspheres, by application

TABLE 20 EMBOLOThERAPY MARKET FOR MICROSPHERES, BY APPLICATION, 2019–2026 (USD MILLION)

6.2.2.3 Embolotherapy market for microspheres, by Procedure

TABLE 21 EMBOLOThERAPY MARKET FOR MICROSPHERES, BY PROCEDURE, 2019–2026 (USD MILLION)

6.2.2.4 Embolotherapy market for microspheres, by end user

TABLE 22 EMBOLOOTHERAPY MARKET FOR MICROSPHERES, BY END USER, 2019–2026 (USD MILLION)

6.3 EMBOLIZATION COILS

TABLE 23 EMBOLIC COILS OFFERED BY MAJOR MARKET PLAYERS

TABLE 24 EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 25 EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY REGION, 2019–2026 (USD MILLION)

6.3.1 DETACHABLE COILS

6.3.1.1 Detachable coils can be retracted and redeployed a number of times until satisfactory placement is reached, which is a key advantage of this product segment

TABLE 26 EMBOLOOTHERAPY MARKET FOR DETACHABLE COILS, BY REGION, 2019–2026 (USD MILLION)

6.3.1.2 Embolotherapy market for detachable coils, by application

TABLE 27 EMBOLOOTHERAPY MARKET FOR DETACHABLE COILS, BY APPLICATION, 2019–2026 (USD MILLION)

6.3.1.3 Embolotherapy market for detachable coils, by Procedure

TABLE 28 EMBOLOOTHERAPY MARKET FOR DETACHABLE COILS, BY PROCEDURE, 2019–2026 (USD MILLION)

6.3.1.4 Embolotherapy market for detachable coils, by end user

TABLE 29 EMBOLOOTHERAPY MARKET FOR DETACHABLE COILS, BY END USER, 2019–2026 (USD MILLION)

6.3.2 PUSHABLE COILS

6.3.2.1 The use of pushable coils increases the risk of non-target vascular blockages, thus restricting their use in various applications

TABLE 30 EMBOLOOTHERAPY MARKET FOR PUSHABLE COILS, BY REGION, 2019–2026 (USD MILLION)

6.3.2.2 Embolotherapy market for pushable coils, by application

TABLE 31 EMBOLOOTHERAPY MARKET FOR PUSHABLE COILS, BY APPLICATION, 2019–2026 (USD MILLION)

6.3.2.3 Embolotherapy market for pushable coils, by Procedure

TABLE 32 EMBOLOOTHERAPY MARKET FOR PUSHABLE COILS, BY PROCEDURE, 2019–2026 (USD MILLION)

6.3.2.4 Embolotherapy market for pushable coils, by end user

TABLE 33 EMBOLOOTHERAPY MARKET FOR PUSHABLE COILS, BY END USER, 2019–2026 (USD MILLION)

6.4 EMBOLIC PLUG SYSTEMS

TABLE 34 EMBOLOOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY

REGION, 2019–2026 (USD MILLION)

6.4.1 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY APPLICATION

TABLE 35 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY APPLICATION, 2019–2026 (USD MILLION)

6.4.2 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY PROCEDURE

TABLE 36 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY PROCEDURE, 2019–2026 (USD MILLION)

6.4.3 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY END USER

TABLE 37 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY END USER, 2019–2026 (USD MILLION)

6.5 DETACHABLE BALLOONS

6.5.1 ADVERSE EVENTS ASSOCIATED WITH THE USE OF DETACHABLE BALLOONS SUCH AS BALLOON RUPTURE, FAILURE, OR SHRINKAGE MAY LIMIT THE UTILIZATION OF THIS EMBOLIC DEVICE

TABLE 38 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY REGION, 2019–2026 (USD MILLION)

6.5.2 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY APPLICATION

TABLE 39 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY APPLICATION, 2019–2026 (USD MILLION)

6.5.3 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY PROCEDURE

TABLE 40 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY PROCEDURE, 2019–2026 (USD MILLION)

6.5.4 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY END USER

TABLE 41 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY END USER, 2019–2026 (USD MILLION)

6.6 SUPPORT DEVICES

TABLE 42 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

TABLE 43 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY REGION, 2019–2026 (USD MILLION)

6.6.1 MICROCATHETERS

6.6.1.1 Advancements and regulatory approvals in microcatheter technologies are expected to result in their wider adoption

TABLE 44 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY REGION,

2019–2026 (USD MILLION)

6.6.1.2 Embolotherapy market for microcatheters, by application

TABLE 45 EMBOLOOTHERAPY MARKET FOR MICROCATHETERS, BY APPLICATION, 2019–2026 (USD MILLION)

6.6.1.3 Embolotherapy market for microcatheters, by Procedure

TABLE 46 EMBOLOOTHERAPY MARKET FOR MICROCATHETERS, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 47 EMBOLOOTHERAPY MARKET FOR MICROCATHETERS, BY END USER, 2019–2026 (USD MILLION)

6.6.2 GUIDEWIRES

6.6.2.1 Rising adoption of guidewires among medical professionals owing to their procedural benefits is expected to drive market growth

TABLE 48 EMBOLOOTHERAPY MARKET FOR GUIDEWIRES, BY REGION, 2019–2026 (USD MILLION)

6.6.2.2 Embolotherapy market for guidewires, by application

TABLE 49 EMBOLOOTHERAPY MARKET FOR GUIDEWIRES, BY APPLICATION, 2019–2026 (USD MILLION)

6.6.2.3 Embolotherapy market for guidewires, by Procedure

TABLE 50 EMBOLOOTHERAPY MARKET FOR GUIDEWIRES, BY PROCEDURE, 2019–2026 (USD MILLION)

6.6.2.4 Embolotherapy market for guidewires, by end user

TABLE 51 EMBOLOOTHERAPY MARKET FOR GUIDEWIRES, BY END USER, 2019–2026 (USD MILLION)

7 EMBOLOOTHERAPY MARKET, BY APPLICATION

7.1 INTRODUCTION

TABLE 52 EMBOLOOTHERAPY MARKET, BY APPLICATION, 2019–2026

7.2 ONCOLOGY

TABLE 53 EMBOLOOTHERAPY MARKET FOR ONCOLOGY, BY TYPE, 2019–2026

TABLE 54 EMBOLOOTHERAPY MARKET FOR CANCER, BY REGION, 2019–2026

7.2.1 LIVER CANCER

7.2.1.1 The rising prevalence of liver cancer is expected to drive segment growth

TABLE 55 EMBOLOOTHERAPY MARKET FOR LIVER CANCER, BY REGION, 2019–2026 (USD MILLION)

7.2.2 KIDNEY CANCER

7.2.2.1 Preoperative kidney tumor embolization in the treatment of kidney cancer drives the segment growth

TABLE 56 EMBOLOOTHERAPY MARKET FOR KIDNEY CANCER, BY REGION,

2019–2026 (USD MILLION)

7.2.3 LUNG CANCER

7.2.3.1 Use of arterial embolotherapy in patients with primary lung cancer to drive the segment growth

TABLE 57 EMBOLOOTHERAPY MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)

7.2.3.2 The increasing prevalence of breast cancer is a key factor in the higher adoption of embolotherapy among surgeons

TABLE 58 EMBOLOOTHERAPY MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)

7.2.4 OTHER CANCERS

TABLE 59 EMBOLOOTHERAPY MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)

7.3 PERIPHERAL VASCULAR DISEASES

7.3.1 RISING ADOPTION OF VASCULAR PLUGS IS A KEY FACTOR DRIVING MARKET GROWTH

TABLE 60 EMBOLOOTHERAPY MARKET FOR PERIPHERAL VASCULAR DISEASES, BY REGION, 2019–2026 (USD MILLION)

7.4 NEUROLOGY

TABLE 61 EMBOLOOTHERAPY MARKET FOR NEUROLOGY, BY TYPE, 2019–2026

TABLE 62 EMBOLOOTHERAPY MARKET FOR NEUROLOGY, BY REGION, 2019–2026 (USD MILLION)

7.4.1 BRAIN ANEURYSM

7.4.1.1 Limited availability of reimbursements across major markets may hinder the market growth

TABLE 63 EMBOLOOTHERAPY MARKET FOR BRAIN ANEURYSM, BY REGION, 2019–2026 (USD MILLION)

7.4.2 CEREBRAL ARTERIOVENOUS MALFORMATION

7.4.2.1 Side effects associated with AVM embolization procedures may restrict market growth to a certain extent

TABLE 64 EMBOLOOTHERAPY MARKET FOR CEREBRAL ARTERIOVENOUS MALFORMATION, BY REGION, 2019–2026 (USD MILLION)

7.5 UROLOGY & NEPHROLOGY

TABLE 65 EMBOLOOTHERAPY MARKET FOR UROLOGY & NEPHROLOGY, BY TYPE, 2019–2026 (USD MILLION)

TABLE 66 EMBOLOOTHERAPY MARKET FOR UROLOGY & NEPHROLOGY, BY REGION, 2019–2026 (USD MILLION)

7.5.1 BENIGN PROSTATIC HYPERPLASIA

7.5.1.1 Risks associated with traditional surgery will make patients opt for PAE

treatment

TABLE 67 EMBOLOTHERAPY MARKET FOR BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2019–2026 (USD MILLION)

7.5.1.2 Advantages offered by the UFE over other techniques is a key factor driving market growth

TABLE 68 EMBOLOTHERAPY MARKET FOR UTERINE FIBROIDS, BY REGION, 2019–2026 (USD MILLION)

7.5.2 OTHER UROLOGY & NEPHROLOGY APPLICATIONS

7.5.2.1 Safety and minimal complication with the use of TAE in this segment will drive the market growth

TABLE 69 EMBOLOTHERAPY MARKET FOR OTHER UROLOGY & NEPHROLOGY APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)

7.6 GASTROINTESTINAL DISORDERS

7.6.1 EMBOLIZATION IS A WIDELY ADOPTED PROCEDURE USED TO TREAT LGIB AND UGIB

TABLE 70 EMBOLOTHERAPY MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2019–2026 (USD MILLION)

8 EMBOLOTHERAPY MARKET, BY PROCEDURE

8.1 INTRODUCTION

TABLE 71 EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

8.2 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE)

8.2.1 THE GROWTH OF THIS SEGMENT IS LARGELY DRIVEN DUE TO THE INCREASING INCIDENCE OF UTERINE FIBROIDS & VASCULAR LESIONS

TABLE 72 TRANSCATHETER ARTERIAL EMBOLIZATION MARKET, BY REGION, 2019–2026 (USD MILLION)

8.3 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION (TARE)/SELECTIVE INTERNAL RADIATION THERAPY (SIRT)

8.3.1 BETTER CLINICAL OUTCOMES & INCREASED CANCER SURVIVAL RATE SUPPORTS THE GROWTH OF THIS SEGMENT

TABLE 73 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION MARKET, BY REGION, 2019–2026 (USD MILLION)

8.4 TRANSARTERIAL CHEMOEMBOLIZATION (TACE)

8.4.1 TACE CAN BE USED TO TREAT TUMORS THAT ARE RELATIVELY LARGER IN SIZE, WHICH CANNOT BE EASILY TREATED BY TUMOR ABLATION

TABLE 74 TRANSARTERIAL CHEMOEMBOLIZATION MARKET, BY REGION, 2019–2026

9 EMBOLOThERAPY MARKET, BY END USER

9.1 INTRODUCTION

TABLE 75 EMBOLOThERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)

9.2 HOSPITALS AND CLINICS

9.2.1 RISING INCIDENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH

TABLE 76 EMBOLOThERAPY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2019–2026 (USD MILLION)

9.3 AMBULATORY SURGERY CENTERS

9.3.1 INCREASING AVAILABILITY OF REIMBURSEMENTS TO DRIVE THE ADOPTION OF EMBOLOThERAPY PRODUCTS IN ASCS

TABLE 77 EMBOLOThERAPY MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2019–2026 (USD MILLION)

9.4 OTHER END USERS

TABLE 78 EMBOLOThERAPY MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)

10 EMBOLOThERAPY MARKET, BY REGION

10.1 INTRODUCTION

TABLE 79 EMBOLOThERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)

10.2 NORTH AMERICA

FIGURE 21 NORTH AMERICA: EMBOLOThERAPY MARKET SNAPSHOT

TABLE 80 NORTH AMERICA: EMBOLOThERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 81 NORTH AMERICA: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 82 NORTH AMERICA: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 83 NORTH AMERICA: EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 84 NORTH AMERICA: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

TABLE 85 NORTH AMERICA: EMBOLOThERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)

TABLE 86 NORTH AMERICA: EMBOLOThERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 87 NORTH AMERICA: EMBOLOThERAPY MARKET, BY END USER,

2019–2026 (USD MILLION)

10.2.1 US

10.2.1.1 Increasing R&D investments in the country drives the market growth

TABLE 88 US: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 89 US: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 90 US: EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 91 US: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.2.2 CANADA

10.2.2.1 The rising prevalence of cancer supports market growth in Canada

TABLE 92 CANADA: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 93 CANADA: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 94 CANADA: EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 95 CANADA: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.3 EUROPE

TABLE 96 EUROPE: EMBOLOThERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 97 EUROPE: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 98 EUROPE: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 99 EUROPE: EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 100 EUROPE: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

TABLE 101 EUROPE: EMBOLOThERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)

TABLE 102 EUROPE: EMBOLOThERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 103 EUROPE: EMBOLOThERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.3.1 GERMANY

10.3.1.1 Germany is the fastest growing market in Europe

TABLE 104 GERMANY: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 105 GERMANY: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 106 GERMANY: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 107 GERMANY: EMBOLOOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.3.2 UK

10.3.2.1 The rising geriatric population and the high incidence of chronic diseases support market growth in the UK

TABLE 108 UK: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 109 UK: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 110 UK: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 111 UK: EMBOLOOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.3.3 FRANCE

10.3.3.1 The growing geriatric population coupled with the increasing number of target surgeries to support market growth in France

TABLE 112 FRANCE: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 113 FRANCE: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 114 FRANCE: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 115 FRANCE: EMBOLOOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.3.4 SPAIN

10.3.4.1 Increasing government funding for research to support market growth

TABLE 116 SPAIN: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 117 SPAIN: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 118 SPAIN: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 119 SPAIN: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.3.5 ITALY

10.3.5.1 Rising awareness activities to support market growth

TABLE 120 ITALY: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 121 ITALY: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 122 ITALY: EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 123 ITALY: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.3.6 REST OF EUROPE

TABLE 124 REST OF EUROPE: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 125 REST OF EUROPE: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 126 REST OF EUROPE: EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 127 REST OF EUROPE: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.4 ASIA PACIFIC

FIGURE 22 ASIA PACIFIC: EMBOLOThERAPY MARKET SNAPSHOT

TABLE 128 ASIA PACIFIC: EMBOLOThERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 129 ASIA PACIFIC: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 130 ASIA PACIFIC: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 131 ASIA PACIFIC: EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 132 ASIA PACIFIC: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

TABLE 133 ASIA PACIFIC: EMBOLOThERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)

TABLE 134 ASIA PACIFIC: EMBOLOThERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 135 ASIA PACIFIC: EMBOLOThERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.4.1 JAPAN

10.4.1.1 Presence of universal healthcare reimbursement scenario and growing geriatric population—key factors driving market growth

TABLE 136 JAPAN: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 137 JAPAN: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 138 JAPAN: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 139 JAPAN: EMBOLOOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.4.2 CHINA

10.4.2.1 Increasing patient pool and government initiatives for healthcare development supports market growth

TABLE 140 CHINA: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 141 CHINA: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 142 CHINA: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 143 CHINA: EMBOLOOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.4.3 INDIA

10.4.3.1 Ongoing modernization and infrastructure development in India to support the market growth for embolotherapy

TABLE 144 INDIA: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 145 INDIA: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 146 INDIA: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 147 INDIA: EMBOLOOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.4.4 SOUTH KOREA

10.4.4.1 Rising R&D and promising clinical trials in the country to positively impact market growth

TABLE 148 SOUTH KOREA: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 149 SOUTH KOREA: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS,

BY TYPE, 2019–2026 (USD MILLION)

TABLE 150 SOUTH KOREA: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 151 SOUTH KOREA: EMBOLOOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.4.5 AUSTRALIA

10.4.5.1 Rising research investments and awareness campaigns are the key factors supporting market growth in Australia

TABLE 152 AUSTRALIA: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 153 AUSTRALIA: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 154 AUSTRALIA: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 155 AUSTRALIA: EMBOLOOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.4.6 REST OF ASIA PACIFIC

TABLE 156 REST OF APAC: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 157 REST OF APAC: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 158 REST OF APAC: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 159 REST OF APAC: EMBOLOOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.5 LATIN AMERICA

TABLE 160 LATIN AMERICA: EMBOLOOTHERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 161 LATIN AMERICA: EMBOLOOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 162 LATIN AMERICA: EMBOLOOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 163 LATIN AMERICA: EMBOLOOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 164 LATIN AMERICA: EMBOLOOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

TABLE 165 LATIN AMERICA: EMBOLOOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)

TABLE 166 LATIN AMERICA: EMBOLOOTHERAPY MARKET, BY PROCEDURE,

2019–2026 (USD MILLION)

TABLE 167 LATIN AMERICA: EMBOLOThERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)

10.5.1 BRAZIL

10.5.1.1 Brazil is a key market in Latin America owing to the modernization of healthcare facilities

TABLE 168 BRAZIL: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 169 BRAZIL: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 170 BRAZIL : EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 171 BRAZIL: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.5.2 MEXICO

10.5.2.1 Availability of advanced care and increasing awareness programs are driving market growth in Mexico

TABLE 172 MEXICO: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 173 MEXICO: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 174 MEXICO: EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 175 MEXICO: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.5.3 REST OF LATIN AMERICA

TABLE 176 REST OF LATAM: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 177 REST OF LATAM: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 178 REST OF LATAM: EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 179 REST OF LATAM: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

10.6 MIDDLE EAST & AFRICA

10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN THE MEA

TABLE 180 MIDDLE EAST & AFRICA: EMBOLOThERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 181 MIDDLE EAST & AFRICA: EMBOLOThERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 182 MIDDLE EAST & AFRICA: EMBOLOThERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION)

TABLE 183 MIDDLE EAST & AFRICA: EMBOLOThERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION)

TABLE 184 MIDDLE EAST & AFRICA: EMBOLOThERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)

TABLE 185 MIDDLE EAST & AFRICA: EMBOLOThERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)

TABLE 186 MIDDLE EAST & AFRICA: EMBOLOThERAPY MARKET, BY END USER, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

FIGURE 23 KEY DEVELOPMENTS IN THE EMBOLOThERAPY MARKET FROM 2017 TO 2020

11.2 GLOBAL MARKET SHARE ANALYSIS

11.2.1 GLOBAL EMBOLOThERAPY MARKET SHARE ANALYSIS (2019)

FIGURE 24 GLOBAL EMBOLOThERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)

11.3 COMPETITIVE LEADERSHIP MAPPING

11.3.1 STARS

11.3.2 EMERGING LEADERS

11.3.3 PERVASIVE

11.3.4 PARTICIPANTS

FIGURE 25 EMBOLOThERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)

FIGURE 26 EMBOLOThERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (SME/START-UPS)

11.4 COMPETITIVE SCENARIO

11.4.1 PRODUCT LAUNCHES

TABLE 187 EMBOLOThERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS, 2017–2020

11.4.2 EXPANSIONS

TABLE 188 EMBOLOThERAPY MARKET: EXPANSIONS, 2017–2020

11.4.3 ACQUISITIONS

TABLE 189 EMBOLOThERAPY MARKET: ACQUISITIONS, 2017–2020

12 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, and MnM View)*

12.1 KEY PLAYERS

12.1.1 BOSTON SCIENTIFIC CORPORATION

TABLE 190 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW

FIGURE 27 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT

12.1.2 MERIT MEDICAL SYSTEMS

TABLE 191 MERIT MEDICAL SYSTEMS: BUSINESS OVERVIEW

FIGURE 28 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT

12.1.3 TERUMO CORPORATION

TABLE 192 TERUMO CORPORATION: BUSINESS OVERVIEW

FIGURE 29 TERUMO CORPORATION: COMPANY SNAPSHOT

12.1.4 MEDTRONIC PLC

TABLE 193 MEDTRONIC PLC: BUSINESS OVERVIEW

FIGURE 30 MEDTRONIC PLC: COMPANY SNAPSHOT

12.1.5 ABBOTT LABORATORIES

TABLE 194 ABBOTT LABORATORIES: BUSINESS OVERVIEW

FIGURE 31 ABBOTT LABORATORIES: COMPANY SNAPSHOT

12.1.6 DEPUY SYNTHES (J&J MEDICAL DEVICES)

TABLE 195 DEPUY SYNTHES: BUSINESS OVERVIEW

FIGURE 32 JOHNSON & JOHNSON: COMPANY SNAPSHOT

12.1.7 COOK MEDICAL

TABLE 196 COOK MEDICAL: BUSINESS OVERVIEW

12.1.8 BALT

TABLE 197 BALT: BUSINESS OVERVIEW

12.1.9 SIRTEX MEDICAL LIMITED (PART OF CDH INVESTMENTS)

TABLE 198 SIRTEX MEDICAL LIMITED: BUSINESS OVERVIEW

12.1.10 KANEKA CORPORATION

TABLE 199 KANEKA CORPORATION: BUSINESS OVERVIEW

FIGURE 33 KANEKA CORPORATION: COMPANY SNAPSHOT

12.1.11 STRYKER CORPORATION

TABLE 200 STRYKER CORPORATION: BUSINESS OVERVIEW

FIGURE 34 STRYKER CORPORATION: COMPANY SNAPSHOT

12.2 OTHER PLAYERS

12.2.1 PENUMBRA, INC.

TABLE 201 PENUMBRA, INC.: BUSINESS OVERVIEW

FIGURE 35 PENUMBRA, INC.: COMPANY SNAPSHOT

12.2.2 MERIL LIFE SCIENCES PVT., LTD.

TABLE 202 MERIL LIFE SCIENCES PVT., LTD.: BUSINESS OVERVIEW

12.2.3 ACANDIS GMBH

TABLE 203 ACANDIS GMBH: BUSINESS OVERVIEW

12.2.4 CARDIVA MEDICAL INC. (PART OF HAEMONETICS)

TABLE 204 CARDIVA MEDICAL INC.: BUSINESS OVERVIEW

12.2.5 SHAPE MEMORY MEDICAL, INC.

TABLE 205 SHAPE MEMORY MEDICAL, INC.: BUSINESS OVERVIEW

12.2.6 ARTIO MEDICAL, INC.

TABLE 206 ARTIO MEDICAL, INC.: BUSINESS OVERVIEW

12.2.7 RAPID MEDICAL

TABLE 207 RAPID MEDICAL: BUSINESS OVERVIEW

12.2.8 IMBIOTECHNOLOGIES LTD.

TABLE 208 IMBIOTECHNOLOGIES LTD.: BUSINESS OVERVIEW

12.2.9 EMBOLINE, INC.

TABLE 209 EMBOLINE, INC.: BUSINESS OVERVIEW

*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

13 APPENDIX

13.1 DISCUSSION GUIDE

13.2 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

13.3 AVAILABLE CUSTOMIZATIONS

13.4 RELATED REPORTS

13.5 AUTHOR DETAILS

I would like to order

Product name: Embolotherapy Market by Product (Embolic Agents (Microspheres, Liquid Embolic Agents, Coil), Microcatheters), Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology), Procedure (TACE, TARE), Enduser (Hospital, Clinics, ASC) - Global Forecast to 2026

Product link: <https://marketpublishers.com/r/E3794B95A04EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E3794B95A04EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970